News Sentiment

NGNE sentiment intelligence

Neurogene Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 39.63 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+12.1% over one week, +36.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

(NGNE) Volatility Zones as Tactical Triggers

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 12.1% Price confirming higher
Trend fit Trend active 36.2% over four weeks
Fair value 56.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 37
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Traders Daily 13
Stock Titan 13
Market source 6
Business Wire 6
MT Newswires 4
TradingView 3
simplywall.st 3
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 10
Deals and strategy 6
Guidance 4
Analyst action 4
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Stock Traders Daily Direct company coverage

Liquidity Mapping Around (NGNE) Price Events

This article from Stock Traders Daily provides a detailed analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE) price events. It highlights the potential for sustained positive sentiment, notes elevated downside risk due to a lack of long-term support, and outlines institutional

Tone
Positive 64/100
Event
Balance sheet
Published
07 May 2026 12:40
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (NGNE)

This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models to identify momentum shifts. It highlights weak near-term sentiment challenging long-term strength and outlines three distinct trading strategies with specific entry, target, and stop-loss zones. The

Tone
Negative 28/100
Event
Analyst action
Published
15 Apr 2026 10:24
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

Discipline and Rules-Based Execution in NGNE Response

This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models to provide trading strategies. It notes weak near and mid-term sentiment but a strong long-term outlook, identifying an exceptional risk-reward setup. The analysis offers specific entry, target, and

Tone
Negative 39/100
Event
Guidance
Published
24 Mar 2026 08:06
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

(NGNE) Movement Within Algorithmic Entry Frameworks

The article provides an algorithmic analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting strong sentiment across all horizons and an overweight bias for the stock. It details various institutional trading strategies including position, momentum breakout, and risk

Tone
Positive 71/100
Event
Market update
Published
02 Mar 2026 04:50
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

How (NGNE) Movements Inform Risk Allocation Models

This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, highlighting a mixed sentiment with positive near-term but weak mid-term outlook within a long-term strength context. It provides three distinct institutional trading strategies—Position Trading, Mo

Tone
Positive 70/100
Event
Guidance
Published
19 Feb 2026 03:22
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

(NGNE) and the Role of Price-Sensitive Allocations

This article provides an AI-generated analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk He

Tone
Negative 39/100
Event
Guidance
Published
16 Jan 2026 23:58
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

Responsive Playbooks and the NGNE Inflection

This article provides an AI-driven analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting weak near-term sentiment despite potential long-term strength. It presents specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-

Tone
Negative 29/100
Event
Analyst action
Published
05 Jan 2026 22:50
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

Why (NGNE) Price Action Is Critical for Tactical Trading

This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) price action, highlighting a strong near-term sentiment while a mid-channel oscillation pattern is in play. The analysis identifies an exceptional risk-reward short setup and outlines three distinct AI-generated tra

Tone
Neutral 50/100
Event
Market update
Published
14 Dec 2025 19:32
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

Behavioral Patterns of NGNE and Institutional Flows

This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, highlighting a near-term weak sentiment despite mid-term strength and a broader long-term weak bias. It identifies a significant risk-reward short setup with a target of 41.6% downside versus 0.3% r

Tone
Neutral 50/100
Event
Analyst action
Published
23 Oct 2025 13:56
Source
Stock Traders Daily
Seeking Alpha Direct company coverage

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers (NASDAQ:NGNE)

Neurogene Inc., a clinical-stage gene therapy company, has seen its share price rise significantly since its Nasdaq debut in December 2023. The company is advancing two drug candidates, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease, with key milestones anticipated

Tone
Neutral 50/100
Event
Deals and strategy
Published
26 Mar 2024 14:13
Source
Seeking Alpha
The AI Journal Direct company coverage

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

Neurogene announced the closing of its merger with Neoleukin Therapeutics and a concurrent oversubscribed private placement of $95 million. The newly combined company, trading on NASDAQ as "NGNE," now has approximately $200 million in cash, which is expected to fund its operation

Tone
Positive 74/100
Event
Deals and strategy
Published
19 Dec 2023 18:10
Source
The AI Journal
FinancialContent Direct company coverage

Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX

Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the proposed merger of Neoleukin Therapeutics, Inc. (NLTX) with Neurogene Inc. The investigation aims to determine if the merger adequately values Neoleukin and if the pr

Tone
Neutral 50/100
Event
Deals and strategy
Published
25 Jul 2023 10:49
Source
FinancialContent
Benzinga Direct company coverage

Neoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neu

Neoleukin Therapeutics and Neurogene are merging to form a biotech firm focused on genetic medicines for neurological diseases. The combined company, to be named Neurogene Inc., will focus on advancing Neurogene's pipeline, including NGN-401 for Rett syndrome, and is expected to

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2023 18:39
Source
Benzinga
PharmTech.com Direct company coverage

Neurogene and Neoleukin Announce Merger

Neurogene Inc. and Neoleukin Therapeutics, Inc. have announced a definitive merger agreement, with the combined entity set to operate as “Neurogene Inc.” The merger also involves an oversubscribed US$95 million private financing, projecting approximately US$200 million in cash fo

Tone
Positive 73/100
Event
Deals and strategy
Published
18 Jul 2023 14:11
Source
PharmTech.com
GlobeNewswire Direct company coverage

Neurogene and Neoleukin Announce Definitive Merger Agreement

Neurogene and Neoleukin Therapeutics have entered into a definitive merger agreement to form a Nasdaq-listed biotech company focused on genetic medicines for neurological diseases. The combined entity is expected to have approximately $200 million in cash, including a $95 million

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jul 2023 07:39
Source
GlobeNewswire